Answers are grounded in this paper and cite their sources.
<ns3:p>Introduction: CRP, together with albumin, has been included in the risk scoringmodel of both the traditional Glasgow prognostic index (GPS) and its modifiedversion (mGPS), both of which have shown independent prognostic value inpatients with various cancers. However, the utility of the mGPS has not beeninvestigated in patients with muscle invasive bladder cancer (MIBC) eligiblefor radical conservative or palliative treatment.Aim: The aim of this study was to determine the associations between 3 differentmodified Glasgow prognostic indices and progression-free survival (PFS) and overall survival (OS). For the analysis, authors of this study used the standard modified mGPS, and twoof their own modified GPS that they created: the new nGPS index, whose scales were calculated using a CRPconcentration of 5 mg/l (nGPS), and the calculated cGPS index based on optimal CRP and albumin cut-offvalues calculated from ROC curve analysis.Material and methods: A retrospective observational study was conducted in a group of 136 patients withMIBC eligible for radical conservative or palliative treatment. CRP and albumin concentrations were measuredin all patients prior to treatment. The Kaplan-Meier method was used to assess the association between theGPS studied and overall survival (OS) and cancer progression-free time (PFS). The log-rank test was used todetermine differences between groups.Results: Analysis of the probability of PFS in patients treated with radical conservative treatment for mGPS,nGPS and cGPS showed a significant difference only for authors of this article proposed cGPS based on CRPand albumin levels calculated from ROC curve analysis, patients with cGPS 1 or 2 had a significantly shorterprogression-free time compared to the group with cGPS 0 (p = 0.0349). Kaplan-Meier analysis showed a significantdifference in patients' OS between scales (“0”, “1”, “2”) of all GPS assessed, but the differences betweenscales “0” and “1” for our proposed cGPS and nGPS were highly statistically significant (<0.001) compared tomGPS (p = 0.02). Furthermore, OS of patients with scale “0” were highest in the group with our calculated cGPS(79.3%), slightly lower in the group with authors of this study second proposed nGPS (75.6%) and lowest inthe group with standard mGPS (70.1%). Authors of this article also found that palliatively treated patients hadsignificantly shorter 2-year survival with scale “2” compared to the group with scale “0” or “1” in both of authorsproposed GPS: cGPS: 22.6% vs. 64.0% (p = 0.0005), nGPS: 20.8% vs. 56.3% (p = 0.0026).Conclusions: • The cGPS proposed by the authors of this article, based on optimal cut-off values of CRP andalbumin concentrations determined by ROC curves, showed to be a better prognostic factor for PFS in patientswith MIBC treated with radical conservative therapy compared to nGPS and mGPS.• Both nGPS and cGPS, authors modified indices, showed to be negative prognostic factors for OS in patientstreated with radical conservative treatment with disease progression.• nGPS and cGPS appear to be better markers for predicting disease progression, overall survival compared tothe standard mGPS based on CRP concentration = 10 mg/l.</ns3:p>
No takes yet. Share an insight, caveat, or question.
Rychlik et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: